Home NDC 46287-037 NORLIQVA
Product NDC 46287-037
11-digit product format 462870037
Labeler code 46287
Product ID 46287-037_4fee8eba-2fa2-4a9c-884a-ccec171e1977
Type HUMAN PRESCRIPTION DRUG
Nonproprietary name amlodipine
Dosage form SOLUTION
Route ORAL
Labeler CMP Pharma, Inc.
Application NDA214439
Marketing category NDA
Marketing start 2026-03-02
Substance AMLODIPINE
Active strength 1 mg/mL
Pharmacologic classes Calcium Channel Antagonists [MoA], Calcium Channel Blocker [EPC], Cytochrome P450 3A Inhibitors [MoA], Dihydropyridine Calcium Channel Blocker [EPC], Dihydropyridines [CS]
NDC exclude flag No
Listing certified through 2027-12-31
Current FDA listing Yes Source provenance: Browse the complete Orange Book source catalog · source snapshot 42 .
Orange Book products# Current product rows page 1 of 1 · 1 matching rows.
Application-product, Trade name, Ingredient table Application-product Trade name Ingredient Strength Dosage form / route TE codes RLD / RS Approval date N214439-001 NORLIQVA AMLODIPINE BESYLATE EQ 1MG BASE/ML SOLUTION / ORAL RLD, RS 2022-02-24
Orange Book patents# Current patent rows page 1 of 1 · 18 matching rows.
Application-product, Patent, Expiration table Application-product Patent Expiration Use code Coverage / status Submission date N214439-001 11253474 2041-02-24 U-3309 Drug product 2022-02-28 N214439-001 11253474 2041-02-24 U-3310 Drug product 2022-02-28 N214439-001 11253474 2041-02-24 U-3311 Drug product 2022-02-28 N214439-001 11458095 2041-02-24 U-3309 Drug product 2022-10-05 N214439-001 11458095 2041-02-24 U-3310 Drug product 2022-10-05 N214439-001 11458095 2041-02-24 U-3311 Drug product 2022-10-05 N214439-001 11723866 2041-02-24 U-3309 Drug product 2023-08-18 N214439-001 11723866 2041-02-24 U-3310 Drug product 2023-08-18 N214439-001 11723866 2041-02-24 U-3311 Drug product 2023-08-18 N214439-001 12005141 2041-02-24 U-3309 Drug product 2024-06-28 N214439-001 12005141 2041-02-24 U-3310 Drug product 2024-06-28 N214439-001 12005141 2041-02-24 U-3311 Drug product 2024-06-28 N214439-001 12226528 2041-02-24 U-3309 Drug product 2025-02-27 N214439-001 12226528 2041-02-24 U-3310 Drug product 2025-02-27 N214439-001 12226528 2041-02-24 U-3311 Drug product 2025-02-27 N214439-001 12440441 2041-02-24 U-3309 Drug product 2025-10-23 N214439-001 12440441 2041-02-24 U-3310 Drug product 2025-10-23 N214439-001 12440441 2041-02-24 U-3311 Drug product 2025-10-23
Observed Orange Book product history# Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
Captured, Edition, Application-product table Captured Edition Application-product Trade name Strength Dosage form / route Product TE source text RLD / RS Approval date Source SHA-256 2026-08-18 06:07:40 2026-07 N214439-001 NORLIQVA EQ 1MG BASE/ML SOLUTION / ORAL RLD, RS 2022-02-24 caaa826d4ba7…2026-02-19 14:30 UTC 2026-02 N214439-001 NORLIQVA EQ 1MG BASE/ML SOLUTION / ORAL RLD, RS 2022-02-24 011fe1cb6892…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N214439-001 NORLIQVA EQ 1MG BASE/ML SOLUTION / ORAL RLD, RS 2022-02-24 31067a03dcf5…2025-08-23 18:47 UTC 2025-08 N214439-001 NORLIQVA EQ 1MG BASE/ML SOLUTION / ORAL RLD, RS 2022-02-24 6a471c1ec25d…2025-03-22 03:13 UTC · 3 captures of this ZIP 2025-03 N214439-001 NORLIQVA EQ 1MG BASE/ML SOLUTION / ORAL RLD, RS 2022-02-24 fd3edfee7708…2025-02-26 10:13 UTC · 3 captures of this ZIP 2025-02 N214439-001 NORLIQVA EQ 1MG BASE/ML SOLUTION / ORAL RLD, RS 2022-02-24 b8a1b40f171c…2025-01-19 17:59 UTC · 7 captures of this ZIP 2025-01 N214439-001 NORLIQVA EQ 1MG BASE/ML SOLUTION / ORAL RLD, RS 2022-02-24 03ed91905a0d…2024-12-13 21:23 UTC · 2 captures of this ZIP 2024-12 N214439-001 NORLIQVA EQ 1MG BASE/ML SOLUTION / ORAL RLD, RS 2022-02-24 2680178bc6a6…2024-09-14 05:58 UTC · 2 captures of this ZIP 2024-09 N214439-001 NORLIQVA EQ 1MG BASE/ML SOLUTION / ORAL RLD, RS 2022-02-24 5bbf6a4d5a75…2024-11-08 22:44 UTC · 3 captures of this ZIP 2024-11 N214439-001 NORLIQVA EQ 1MG BASE/ML SOLUTION / ORAL RLD, RS 2022-02-24 d8e5a09893c0…2024-10-29 15:01 UTC 2024-10 N214439-001 NORLIQVA EQ 1MG BASE/ML SOLUTION / ORAL RLD, RS 2022-02-24 d06236e962d9…2024-08-13 05:28 UTC · 3 captures of this ZIP 2024-08 N214439-001 NORLIQVA EQ 1MG BASE/ML SOLUTION / ORAL RLD, RS 2022-02-24 79d66fd596c7…2024-07-13 05:37 UTC · 2 captures of this ZIP 2024-07 N214439-001 NORLIQVA EQ 1MG BASE/ML SOLUTION / ORAL RLD, RS 2022-02-24 301d65b070ca…2024-06-18 03:08 UTC · 5 captures of this ZIP 2024-06 N214439-001 NORLIQVA EQ 1MG BASE/ML SOLUTION / ORAL RLD, RS 2022-02-24 1e350fbaab3a…2024-05-31 18:47 UTC 2024-05 N214439-001 NORLIQVA EQ 1MG BASE/ML SOLUTION / ORAL RLD, RS 2022-02-24 8072bd15b7f6…2022-06-29 02:47 UTC · 2 captures of this ZIP 2022-06 N214439-001 NORLIQVA EQ 1MG BASE/ML SOLUTION / ORAL RLD, RS 2022-02-24 5c6f7cd8ea54…2022-04-08 23:34 UTC 2022-04 N214439-001 NORLIQVA EQ 1MG BASE/ML SOLUTION / ORAL RLD, RS 2022-02-24 5d02ea3f76ae…2022-04-04 05:41 UTC 2022-04 N214439-001 NORLIQVA EQ 1MG BASE/ML SOLUTION / ORAL RLD, RS 2022-02-24 4b0b4de00fa7…2024-03-16 18:09 UTC · 4 captures of this ZIP 2024-03 N214439-001 NORLIQVA EQ 1MG BASE/ML SOLUTION / ORAL RLD, RS 2022-02-24 6a51e52b5d6a…2024-02-18 07:12 UTC 2024-02 N214439-001 NORLIQVA EQ 1MG BASE/ML SOLUTION / ORAL RLD, RS 2022-02-24 1c564ffb4f44…2023-12-20 04:57 UTC 2023-12 N214439-001 NORLIQVA EQ 1MG BASE/ML SOLUTION / ORAL RLD, RS 2022-02-24 ea1830bbd6c7…2023-11-28 05:40 UTC · 2 captures of this ZIP 2023-11 N214439-001 NORLIQVA EQ 1MG BASE/ML SOLUTION / ORAL RLD, RS 2022-02-24 a72a2bbeb626…2023-10-25 00:34 UTC · 2 captures of this ZIP 2023-10 N214439-001 NORLIQVA EQ 1MG BASE/ML SOLUTION / ORAL RLD, RS 2022-02-24 9b2671bbb829…2023-07-15 15:27 UTC · 2 captures of this ZIP 2023-07 N214439-001 NORLIQVA EQ 1MG BASE/ML SOLUTION / ORAL RLD, RS 2022-02-24 a67488948f0b…2023-06-13 01:57 UTC · 3 captures of this ZIP 2023-06 N214439-001 NORLIQVA EQ 1MG BASE/ML SOLUTION / ORAL RLD, RS 2022-02-24 3f0d92c62455…2023-05-13 08:27 UTC 2023-05 N214439-001 NORLIQVA EQ 1MG BASE/ML SOLUTION / ORAL RLD, RS 2022-02-24 053a50430f4f…2023-01-26 05:58 UTC 2023-01 N214439-001 NORLIQVA EQ 1MG BASE/ML SOLUTION / ORAL RLD, RS 2022-02-24 3bdfa0b2c4d7…2022-11-12 20:34 UTC · 5 captures of this ZIP 2022-11 N214439-001 NORLIQVA EQ 1MG BASE/ML SOLUTION / ORAL RLD, RS 2022-02-24 3a93d1ddd44b…2022-10-28 04:53 UTC 2022-10 N214439-001 NORLIQVA EQ 1MG BASE/ML SOLUTION / ORAL RLD, RS 2022-02-24 f41ea6bd6efb…2022-09-29 23:25 UTC 2022-09 N214439-001 NORLIQVA EQ 1MG BASE/ML SOLUTION / ORAL RLD, RS 2022-02-24 e64feba35796…2022-07-09 03:26 UTC · 3 captures of this ZIP 2022-07 N214439-001 NORLIQVA EQ 1MG BASE/ML SOLUTION / ORAL RLD, RS 2022-02-24 cb3db0bc1861…2026-07-26 02:55 UTC · 3 captures of this ZIP 2026-06 N214439-001 NORLIQVA EQ 1MG BASE/ML SOLUTION / ORAL RLD, RS 2022-02-24 a50c72e98297…
Observed Orange Book patent history# Patent history page 1 of 8 · 304 observed states.
Captured, Edition, Application-product table Captured Edition Application-product Patent Expiration Use code Coverage / status Submission date Source SHA-256 2026-08-18 06:07:40 2026-07 N214439-001 11253474 2041-02-24 U-3309 Drug product 2022-02-28 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N214439-001 11253474 2041-02-24 U-3310 Drug product 2022-02-28 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N214439-001 11253474 2041-02-24 U-3311 Drug product 2022-02-28 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N214439-001 11458095 2041-02-24 U-3309 Drug product 2022-10-05 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N214439-001 11458095 2041-02-24 U-3310 Drug product 2022-10-05 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N214439-001 11458095 2041-02-24 U-3311 Drug product 2022-10-05 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N214439-001 11723866 2041-02-24 U-3309 Drug product 2023-08-18 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N214439-001 11723866 2041-02-24 U-3311 Drug product 2023-08-18 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N214439-001 11723866 2041-02-24 U-3310 Drug product 2023-08-18 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N214439-001 12005141 2041-02-24 U-3311 Drug product 2024-06-28 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N214439-001 12005141 2041-02-24 U-3309 Drug product 2024-06-28 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N214439-001 12005141 2041-02-24 U-3310 Drug product 2024-06-28 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N214439-001 12226528 2041-02-24 U-3309 Drug product 2025-02-27 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N214439-001 12226528 2041-02-24 U-3310 Drug product 2025-02-27 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N214439-001 12226528 2041-02-24 U-3311 Drug product 2025-02-27 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N214439-001 12440441 2041-02-24 U-3309 Drug product 2025-10-23 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N214439-001 12440441 2041-02-24 U-3311 Drug product 2025-10-23 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N214439-001 12440441 2041-02-24 U-3310 Drug product 2025-10-23 caaa826d4ba7…2026-02-19 14:30 UTC 2026-02 N214439-001 11253474 2041-02-24 U-3309 Drug product 2022-02-28 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N214439-001 11253474 2041-02-24 U-3310 Drug product 2022-02-28 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N214439-001 11253474 2041-02-24 U-3311 Drug product 2022-02-28 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N214439-001 11458095 2041-02-24 U-3309 Drug product 2022-10-05 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N214439-001 11458095 2041-02-24 U-3310 Drug product 2022-10-05 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N214439-001 11458095 2041-02-24 U-3311 Drug product 2022-10-05 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N214439-001 11723866 2041-02-24 U-3309 Drug product 2023-08-18 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N214439-001 11723866 2041-02-24 U-3311 Drug product 2023-08-18 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N214439-001 11723866 2041-02-24 U-3310 Drug product 2023-08-18 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N214439-001 12005141 2041-02-24 U-3311 Drug product 2024-06-28 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N214439-001 12005141 2041-02-24 U-3309 Drug product 2024-06-28 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N214439-001 12005141 2041-02-24 U-3310 Drug product 2024-06-28 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N214439-001 12226528 2041-02-24 U-3309 Drug product 2025-02-27 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N214439-001 12226528 2041-02-24 U-3310 Drug product 2025-02-27 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N214439-001 12226528 2041-02-24 U-3311 Drug product 2025-02-27 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N214439-001 12440441 2041-02-24 U-3309 Drug product 2025-10-23 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N214439-001 12440441 2041-02-24 U-3311 Drug product 2025-10-23 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N214439-001 12440441 2041-02-24 U-3310 Drug product 2025-10-23 011fe1cb6892…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N214439-001 11253474 2041-02-24 U-3309 Drug product 2022-02-28 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N214439-001 11253474 2041-02-24 U-3310 Drug product 2022-02-28 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N214439-001 11253474 2041-02-24 U-3311 Drug product 2022-02-28 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N214439-001 11458095 2041-02-24 U-3309 Drug product 2022-10-05 31067a03dcf5…
Additional Listing Data#
Finished product Yes
Brand name base NORLIQVA
Listing expiration 2027-12-31 Active Ingredients# Ingredient, Strength table Ingredient Strength AMLODIPINE 1 mg/mL
Harmonized UNII identifiers# UNII identifiers page 1 of 1 · 1 matching rows.
Identifier, FDA.report destination table Identifier FDA.report destination 1J444QC288 Internal UNII lookup
Harmonized RxCUI identifiers# RxCUI identifiers page 1 of 1 · 2 matching rows.
Identifier, FDA.report destination table Identifier FDA.report destination 2599173 Internal RxNorm lookup 2599179 Internal RxNorm lookup
Harmonized SPL set identifiers# SPL set identifiers page 1 of 1 · 1 matching rows.
DailyMed Product Concepts# DailyMed Package Descriptions# Package NDC, Product, Description table Package NDC Product Description Form Quantity Strength SPL version 46287-037-01 NORLIQVA 150 mL in 1 BOTTLE Solution 150 2
openFDA label cross-check# OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
Matched openFDA labels page 1 of 1 · 2 matching rows.
DailyMed RxNorm Mappings# Packages# Package NDC, 11-digit format, Description table Package NDC 11-digit format Description Units Marketing start Sample Exclude flag Status 46287-037-01 46287003701 150 mL in 1 BOTTLE (46287-037-01) 150 ml 2026-03-02 No No Current